Is there relationship between excision repair cross‑complementation 1 expression level and response to treatment and prognosis in an advanced stage lung cancer treated with cisplatin‑based chemotherapy.

AIM: It is important to know the tumor resistance against cisplatin before the treatment of non‑small cell lung cancer (NSCLC). The purpose of this study was to evaluate the response to treatment and survival in patients with NSCLC treated with cisplatin‑based chemotherapy according to excision repair cross‑complementation 1 (ERCC1) expression. MATERIALS AND METHODS: Among 119 patients treated with cisplatin and vinorelbine or docetaxel, 39 (32%) patients enrolled who have enough tumor tissue to analyze ERCC1 expression. ERCC1 expression defined as negative in score 0‑1, positive in score 2‑3. RESULTS: There was no difference between ERCC1 positive and negative groups (P = 0.63). Mean survival was 14.7 months (95% confidence interval [CI]; 10.0‑19.3 month) in ERCC1 negative group, 10.9 months (95% CI; 7.4‑14.3 month) in ERCC1 positive group (P = 0.23). Progression free survival was 7.9 months in ERCC1 negative group (95% CI; 5.8‑9.9 months), 6.2 months in ERCC1 positive group (95% CI; 4.0‑8.5 months) (P = 0.27). CONCLUSION: Identification of ERCC1expression level of tumor tissues in NSCLC patients before treatment was not useful in prediction of treatment response and prognosis.